Potential new therapies ROS-based in CLL: an innovative paradigm in the induction of tumor cell apoptosis
This injection helps regulate your sleep cycle, appetite, and overall mood while decreasing fatigue and increasing energy

Disclosures: Maria Stepanova: Nothing to Disclose, Robert Wong: Theratechnologies: Grant/Research Support, Durect: Grant/Research Support, Gilead Sciences: Grant/Research Support, Exact Sciences: Grant/Research Support, Theratechnologies: Grant/Research Support, Durect Corporation: Grant/Research Support, Ashwani Singal: Nothing to Disclose, Veronica Nguyen: Nothing to Disclose, Linda Henry: Nothing to Disclose, Saleh Alqahtani: Nothing to Disclose, Zobair Younossi: Nothing to Disclose 1510 PRIOR DIAGNOSIS OF DECOMPENSATED ALCOHOL-ASSOCIATED LIVER DISEASE DOES NOT INCREASE RISK OF ALCOHOL RELAPSE DURING TRANSPLANT EVALUATION AND MAY INCREASE RISK OF POST-TRANSPLANT ALCOHOL RELAPS Sasha Deutsch-Link 1 Kevin Wang 1 Weiyu Wu 2 Allison Kwong 2 Kawthar Mohamed 3 Nicholas Lim 3 Katherine Cooper 4 Deepika Devuni 4 Anjana Rajan 5 Amanda Cheung 6 Kaleb Tesfai 7 Veeral Ajmera 8 Hersh Shroff 1 , 1 UNC Chapel Hill, 2 Stanford University Medical Center, 3 University of Minnesota, 4 University of Massachusetts, 5 Northwestern Feinberg School of Medicine, 6 Northwestern Memorial Hospital/Northwestern University, 7 University of California San Diego, 8 University of California, San Diego Background: Access to liver transplant (LT) patients with alcohol-associated liver disease (ALD) has expanded in the past decade

The study design employed was randomized controlled trials (RCTs) Table 1